Intermediate‐term survival and functional outcomes of COVID‐19 extracorporeal membrane oxygenation patients

• Published in: Journal of cardiac surgery Vol. 37; no. 4; pp. 789 - 794
• Main Authors: George, Timothy J., Sheasby, Jenelle, Shih, Emily, Erwin, Gary E., Taylor, Jeff E., Curry, Matthew W., Lilly, Jeffrey C., Vaquera, Key A., Harness‐Brumley, Cayce L., Myers, David P., Michael DiMaio, John
• Format: Journal Article
• Language: English
• Published: United States 01.04.2022
• Subjects: Adult; coronavirus; COVID-19 - therapy; COVID‐19; Extracorporeal Membrane Oxygenation; Humans; Male; Middle Aged; Respiratory Insufficiency - etiology; Respiratory Insufficiency - therapy; Retrospective Studies; SARS-CoV-2; COVID-19; coronavirus; extracorporeal membrane oxygenation
• ISSN: 0886-0440; 1540-8191
• DOI: 10.1111/jocs.16284

Background Extracorporeal membrane oxygenation (ECMO) has been associated with acceptable short‐term survival in patients with refractory respiratory failure secondary to coronavirus disease 2019 (COVID‐19) pneumonia. Previous studies have demonstrated acceptable long‐term outcomes in patients supported with ECMO for respiratory failure of other etiologies. However, long‐term survival and functional outcomes in COVID ECMO patients remain unknown. Methods We conducted a retrospective review of all COVID patients requiring ECMO at our hospital. The primary outcomes measured were survival to discharge and contemporary survival. Secondary outcomes included two simple functional assessments: the ongoing need for oxygen supplementation and the ability to return to work. Survival was calculated using the Kaplan–Meier method. Hazard ratios were calculated using Cox hazards regression models. Results From 2020 to 2021, 48 COVID patients have been supported with ECMO at our hospital. Four patients remain on support and were excluded from further analysis. The average age was 47 ± 8 years, 34 (77%) were males, and the plurality (19, 43%) were Hispanic. Median duration of support was 23 (12–51) days. Median follow‐up was 106 (29–226) days. Survival to discharge was 59%. Kaplan–Meier 180‐day survival was 51%. Long‐term survival conditioned on survival to discharge was 89%. In evaluating functional outcomes, the overwhelming majority of patients no longer required oxygen supplementation (74%), and most had returned to work (52%). Conclusion In conclusion, COVID ECMO patients have acceptable intermediate‐term survival with adequate functional recovery.